About insomnia
Insomnia or sleeplessness is characterized by the difficulty in falling asleep or remaining asleep, resulting in poor quality of sleep or little sleep. Sleeplessness can be acute or chronic. Work-related stress is the more common factor for acute or primary insomnia, while medical conditions, such as arthritis, or medicines, such as amphetamines, and substances, such as cocaine, are the common factors for chronic insomnia.
Technavio's analysts forecast the global insomnia market to decline at a CAGR of 3.08% over the period 2014-2019.
Covered in this report
The report includes the present scenario and the growth prospects of the global insomnia market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used for the treatment of insomnia.
Technavio's report, Global Insomnia Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• Eisai
• Merck
• Pfizer
• Sanofi
• Takeda
Other prominent vendors
• Astellas
• Biocodex
• Dainippon Sumitomo
• ECR Pharmaceuticals (Valeant)
• Fidia Farmaceutici
• Flynn Pharma
• Johnson & Johnson
• Juste
• Meda
Key market driver
• Unmet medical needs
• For a full, detailed list, view our report
Key market challenge
• Dominance of generic products
• For a full, detailed list, view our report
Key market trend
• Emerging drugs targeting orexin receptors
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Insomnia: An overview
Introduction
Epidemiology
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Pipeline portfolio
Examples of pipeline candidates
PART 08: Market segmentation by type of formulation
Tablets
Capsules
Mist formulation
PART 09: Market segmentation by symptom
Market overview
Poor-quality sleep
Difficulties with sleep onset and/or maintenance
Others
PART 10: Geographical segmentation
Market overview
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
Competitive scenario
Market share analysis
Other prominent vendors
PART 17: Key vendor analysis
Eisai
Merck
Pfizer
Sanofi
Takeda
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global insomnia drugs market 2014-2019 ($ billions)
Exhibit 03: Key performance indicators of global insomnia drugs market
Exhibit 04: Five forces analysis
Exhibit 05: Pipeline portfolio
Exhibit 06: Market segmentation by type of formulation
Exhibit 07: Market segmentation by symptom
Exhibit 08: Geographical segmentation 2014
Exhibit 09: Global insomnia drugs market: Key drivers
Exhibit 10: Impact of drivers
Exhibit 11: Global insomnia drugs market: Key challenges
Exhibit 12: Impact of drivers and challenges
Exhibit 13: Global insomnia drugs market: Emerging trends
Exhibit 14: Lunesta sales in North America 2011-2014 ($ millions)
Exhibit 15: Lunesta sales in Japan 2013-2014 ($ millions)
Exhibit 16: Ambien: Global sales 2011-2014 ($ millions)
Exhibit 17: Ambien sales in Western Europe 2011-2014 ($ millions)
Exhibit 18: Ambien sales in the US 2011-2014 ($ millions)
Exhibit 19: Ambien sales in emerging markets 2011-2014 ($ millions)
Exhibit 20: Ambien sales in ROW 2011-2014 ($ millions)
Exhibit 21: Rozerem: Global sales 2011-2013 ($ millions)
Exhibit 22: Rozerem sales in Japan 2012-2014 ($ millions)
Exhibit 23: Takeda: Business segmentation by revenue 2015
Exhibit 24: Takeda: Business segmentation by revenue 2014 and 2015 ($ millions)
Exhibit 25: Takeda: Geographical segmentation by revenue 2015
